Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with, a global biotech company, to support the company’s medical psychedelic treatments. Awakn Life Sciences is a global biotech company that leads the field of psychedelic medicine for the treatment of addiction. In October 2021 commenced the implementation of the Monsenso Digital Health Solution in Awakn Life Sciences clinical practice as a tool for supporting patients throughout their treatment while capturing real-world patient insights to inform clinical decision-making and personalised treatment.

Mental illness and addiction are some of the biggest public health challenges facing the global community.

Nearly one billion people worldwide suffer from mental illness, for which there are too few effective treatments available beyond coping strategies and treating symptoms. With global spending on mental health estimated to reach $16 trillion by 2030 (as measured by lost economic output)[1], it is critical that effective new treatments are developed to address the current gaps. Psychedelic-assisted therapy has emerged as a potential solution to this treatment vacuum. In the early 20th century, these substances were severely restricted and had a negative connotation. Today, however, a growing body of evidence and urgent unmet patient needs have led clinicians and regulators to consider them as a viable treatment option.

Psychedelic-Assisted Psychotherapy represents a paradigm shift in psychiatric treatment

Psychedelic drugs are substances that alter perception and mood and affect various cognitive processes. When used in conjunction with psychotherapy, they can put patients in a temporary state where they can better process memories, emotions, and past traumas[2], allowing for processing that enables subjects to let go of things that have previously troubled them[3]. For the same reason, psychedelic-assisted psychotherapy has shown effective in treating historically difficult-to-treat illnesses[4] and is today considered a promising game-changer in psychiatric treatment[5,6,7].

While psychedelics have spurred great interest in the life science industry, only a few psychedelic companies are currently treating patients in the clinical setting. Awakn Life Sciences launched the UK’s first psychedelic-assisted clinic in Bristol, followed by London and Manchester, offering evidence-based psychedelic therapies for addiction and other mental health indications, and has also opened a clinic in Oslo, Norway with plans to scale across Europe quickly.

In October 2021, Awakn Life Science commenced implementation of the Monsenso Digital Health Solution in its clinical practice to support patients throughout their treatment journey and to capture real-world data to inform clinicians’ decision making for personalised patient support and management.

“We are excited to work with Awakn Life Science to support new treatment options for people who have experienced insufficient treatment results. We look forward to partnering with Awakn Life Sciences and be part of their growth journey” says CEO of Monsenso, Thomas Lethenborg.

Awakn’s CEO, Anthony Tennyson added “There’s such a critical need to provide solutions and hope to people suffering from mental illnesses and addiction. We’re excited to partner with Monsenso to better engage with clients throughout their treatment, gain insights to help inform clinical decisions and improve health outcomes, and generate insights that inform our research and treatment development programs”.

About Awakn Life Science Awakn Life Sciences is a publicly-traded (NEO: AWKN) (OTCQB: AWKNF) biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of worldleading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies and enabling technologies to treat Addiction.

About Monsenso Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Sources:

[1] https://www.weforum.org/agenda/2020/10/mental-health-day-covid19-coronavirus-global/

[2] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[3] Jennifer Mitchell, neuroscientist and professor in the departments of neurology, psychiatry and behavioral sciences at the University of California San Francisco.

[4] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

[5] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[6] https://www.scientificamerican.com/article/a-renaissance-for-psychedelics-could-fill-a-long-standing-treatment-gap-forpsychiatric-disorders/

[7] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

Monsenso moves into a new disorder area with a new project covering Multiple Sclerosis

Monsenso moves into a new disorder area with a new project covering Multiple Sclerosis

Monsenso, leading provider of digital solutions for mental health, moves into a new disorder area with a project covering Multiple Sclerosis (MS). The project is part of the HedaX research project and is conducted jointly with the Danish Multiple Sclerosis Society

The aim of the project, led by Lasse Skovgaard from the Danish Multiple Sclerosis Society, is to explore whether data-driven insight from daily self-assessments can empower users to better manage their disease.

In Denmark, approximately 17.200 people have Multiple Sclerosis (MS), and worldwide there are 2.1 million people diagnosed with MS. MS is an autoimmune disease in which the body’s immune system (autoantibodies) begins to attack and destroy the body’s own nerve cells. MS is a progressive disorder that can affect different places in the central nervous system, why symptoms and disabilities are manifold. Due to the broad heterogeneity among the MS patients’ disease courses, it is difficult to personalise a treatment course for better outcomes.

The aim of the study, therefore, is to validate whether data-driven insight from daily self-assessments can empower users and serve as a tool for individual disease management.

Study participants will be provided with the Monsenso app to assess daily self-assessments of symptoms, lifestyle measures and quality of life. Through visualisation of the historical data, the users can gain better insight into the behaviours that trigger their symptoms, thereby empowering them to better manage their disease.

The project is part of the HedaX research project, funded by the Innovation Fund Denmark, which involves ten public and private partners working together to develop a digital platform to ensure health data is securely captured and shared between individuals, healthcare professionals and researchers. The HedaX-project initially covered cancer and bipolar patients but will now be extended to cover MS patients.

‘’The project with Monsenso offers an opportunity to work closely with a patient organisation and determine whether patients can manage their disease better through the use of a state-of-the-art patient-centred app. The Danish Multiple Sclerosis Society was chosen as a partner because they have a clear ambitious digital strategy’’ says Troels Bierman Mortensen, CEO of DataFair and Project Manager for the HedaX project.

“Multiple Sclerosis is a serious and disabling disease. We are therefore pleased if the Monsenso solution can help to improve future treatments,” says Thomas Lethenborg, CEO of Monsenso.

About the Danish Multiple Sclerosis Society

The Danish Multiple Sclerosis Society is a nationwide organisation with 48 local branches throughout the country and the Faroe Islands and over 60 years of experience in making a difference by leading the way in research, patient support and providing information on Multiple Sclerosis. The organisation counts more than 60,000 members and donors – including 12,000 members with MS which corresponds to 80 percent of all Danish patients with MS.

About Monsenso

Monsenso is an innovative technology company offering a digital health solution. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com

To read the Danish version, click here

For additional information contact:

Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Monsenso signs a contract with the Elite Sports Academy Aarhus (ESAA)

Monsenso signs a contract with the Elite Sports Academy Aarhus (ESAA)

Monsenso signs a contract with the Elite Sports Academy Aarhus (ESAA). The Monsenso digital health solution will be used to promote mental wellbeing among ESAA’s students.

Strong mental health is a prerequisite for top athletes to perform at their best. Yet, top athletes are more vulnerable to psychological distress due to the top performance culture. In response, many clubs have over the recent years taken initiatives to promote mental health among their elite athletes and today sports psychology is as much about mental health, as it is about athletic performance.

ESAA, an Elite Sports Academy located in Aarhus (Denmark), is no exception. With mental health as part of the academy’s core values (Mind, Body, Culture, Team), ESAA seeks to provide their young athletes with self-insight and tools to learn how to master the mental aspects of being an elite athlete.

From August 2021, 75 young elite athletes will be offered the Monsenso mhealth app as part of ESAA’s talent program to track their mental wellbeing daily, while giving them access to “Tools” and “Challenges” to boost their mental health and wellbeing. ‘Tools’ provides the young athletes with coping strategies and ‘Challenges’ helps to learn new skills, like how to gain insight into their emotions, how to develop a positive mindset or improve their confidence.

At the same time, the daily tracking offers ESAA the opportunity to identify and act proactively upon signs and symptoms of mental distress, and hereby to provide preventive support to their young athletes.

 “We are pleased to collaborate with ESAA in this project,” says Thomas Lethenborg, CEO of Monsenso. “The importance of mental health in elite sport, in particular among young athletes, can not be underestimated and we are happy that the Monsenso solution can contribute to that. 

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso